| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Giuseppina Pisano | |
| Anna L Fracanzani | |||
| Lucio Caccamo | |||
| Maria F Donato | |||
| Silvia Fargion | |||
| P2860 | cites work | Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone | Q44079344 |
| Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. | Q44102328 | ||
| Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study | Q44112545 | ||
| Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. | Q44120755 | ||
| Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation | Q44195066 | ||
| Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population | Q44287371 | ||
| Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events | Q44348839 | ||
| Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients | Q44437969 | ||
| Rosiglitazone and cardiotoxicity--weighing the evidence | Q44493811 | ||
| A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. | Q44517537 | ||
| Carotid intima-media thickness as a cardiovascular risk marker in pediatric end-stage renal disease patients on dialysis and in renal transplantation | Q44693823 | ||
| Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study | Q44728781 | ||
| New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. | Q44789148 | ||
| Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation | Q44799989 | ||
| Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis | Q44880772 | ||
| Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage | Q44910175 | ||
| Mycophenolate mofetil monotherapy in liver transplant recipients | Q45076857 | ||
| Role of pretransplant echocardiographic evaluation in predicting outcomes following liver transplantation | Q45347905 | ||
| The impact of obesity on patient survival in liver transplant recipients: a meta-analysis | Q45717878 | ||
| Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study | Q45778081 | ||
| Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. | Q45962265 | ||
| De novo nonalcoholic fatty liver disease after liver transplantation | Q46201190 | ||
| Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus | Q46208453 | ||
| Weight gain and obesity after liver transplantation | Q46386635 | ||
| Carotid intima-media thickness in children and young adults with renal transplant: Internal carotid artery vs. common carotid artery. | Q46919938 | ||
| Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring | Q46943584 | ||
| Posttransplantation weight gain is predominantly due to an increase in body fat mass. | Q47233159 | ||
| Cyclosporin versus tacrolimus for liver transplanted patients | Q24244114 | ||
| Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis | Q24246447 | ||
| Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant | Q26751404 | ||
| Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation | Q26778329 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Chronic renal failure after transplantation of a nonrenal organ | Q28204928 | ||
| Tacrolimus/cerivastatin interaction study in liver transplant recipients | Q28345569 | ||
| Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization | Q28540791 | ||
| The metabolic syndrome | Q29616309 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| Non-alcoholic fatty liver disease and liver transplantation | Q30251746 | ||
| No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data | Q31039949 | ||
| Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients | Q31921619 | ||
| Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation | Q33887123 | ||
| Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study | Q33937741 | ||
| The use of mycophenolate mofetil in transplant recipients | Q33957200 | ||
| Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients | Q33964050 | ||
| Changes in nutritional status after liver transplantation | Q34067831 | ||
| Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease | Q34365693 | ||
| Hypertension and renal dysfunction in long-term liver transplant recipients | Q34426372 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet | Q34647390 | ||
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 | ||
| Mechanisms involved in the side effects of glucocorticoids | Q35003894 | ||
| Ten years of sirolimus therapy in orthotopic liver transplant recipients | Q35125788 | ||
| The impact of left ventricular hypertrophy on survival in candidates for liver transplantation | Q35128460 | ||
| Alterations of the human gut microbiome in liver cirrhosis | Q35216354 | ||
| Time-varying impact of comorbidities on mortality after liver transplantation: a national cohort study using linked clinical and administrative data. | Q35632387 | ||
| Subclinical cardiovascular changes in pediatric solid organ transplant recipients: A systematic review and meta-analysis. | Q38738848 | ||
| Pharmacological management of nonalcoholic fatty liver disease | Q38853183 | ||
| Approach to the patient with new-onset diabetes after transplant (NODAT). | Q39689746 | ||
| Carotid intima-media thickness after pediatric renal or liver transplantation at high-resolution B-mode ultrasonography. | Q39858528 | ||
| Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation | Q40099584 | ||
| Pretransplant echocardiographic parameters as markers of posttransplant outcomes in liver transplant recipients | Q40272343 | ||
| Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation. | Q41570338 | ||
| Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 | ||
| Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial | Q42058175 | ||
| Reduction in energy expenditure after liver transplantation | Q42507157 | ||
| The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation | Q42686323 | ||
| Mammalian target of rapamycin complex 1 is involved in differentiation of regenerating myofibers in vivo. | Q42847179 | ||
| Cardiovascular risk factors and immunosuppressive regimen after liver transplantation. | Q42910506 | ||
| Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors | Q43000302 | ||
| 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus | Q43031760 | ||
| Is there a link between hepatitis C virus and new onset of diabetes mellitus after liver transplantation? | Q43034760 | ||
| Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression | Q43040996 | ||
| Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study | Q43041766 | ||
| Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score | Q43063709 | ||
| Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". | Q43205304 | ||
| Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis | Q43235832 | ||
| Subclinical atherosclerosis and related risk factors in renal transplant recipients | Q43242967 | ||
| Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial | Q43269347 | ||
| Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation | Q43621567 | ||
| Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation | Q43683086 | ||
| Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality | Q43752482 | ||
| Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis | Q43837544 | ||
| Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States | Q43851672 | ||
| Post-liver transplantation diabetes mellitus: an association with hepatitis C. | Q43966879 | ||
| Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). | Q43993163 | ||
| Immunosuppression impact on long-term cardiovascular complications after liver transplantation | Q44009088 | ||
| Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation | Q47960515 | ||
| Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease | Q47999211 | ||
| Adjustable gastric banding in a morbidly obese patient during liver transplantation | Q48479410 | ||
| Transmission of LDLR mutation from donor through liver transplantation resulting in hypercholesterolemia in the recipient | Q51112616 | ||
| Prospective analysis of carotid arterial wall structure in pediatric renal transplants with ambulatory normotension and in treated hypertensive recipients | Q51116661 | ||
| Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. | Q51328144 | ||
| Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. | Q51338670 | ||
| Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. | Q51345165 | ||
| Cumulative risk of cardiovascular events after orthotopic liver transplantation. | Q51379866 | ||
| Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. | Q51442516 | ||
| Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. | Q51466759 | ||
| Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. | Q51482450 | ||
| Arterial hypertension in liver transplant recipients. | Q51519850 | ||
| Cirrhotic cardiomyopathy. | Q51825727 | ||
| De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. | Q53096322 | ||
| Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. | Q53239745 | ||
| Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease. | Q54735435 | ||
| Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: Time to reconsider immunosuppression regimens? | Q56830090 | ||
| A position statement on NAFLD/NASH based on the EASL 2009 special conference | Q61338101 | ||
| Tricuspid Regurgitation on Echocardiography May Not Be a Predictor of Patient Survival After Liver Transplantation | Q61796557 | ||
| Relation between steroid dose, body composition and physical activity in renal transplant patients | Q73847320 | ||
| Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus | Q74543660 | ||
| Obesity as an independent predictor of posttransplant diabetes mellitus | Q75211754 | ||
| Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial | Q79325082 | ||
| Omega-3 fatty acids and liver disease | Q80060310 | ||
| Abnormal carotid artery structure and function in children and adolescents with successful renal transplantation | Q80228077 | ||
| The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis | Q80455381 | ||
| Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy | Q81051294 | ||
| Modified Charlson comorbidity index for predicting survival after liver transplantation | Q81517942 | ||
| NAFLD recurrence in liver transplant recipients | Q83240524 | ||
| Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels | Q83259513 | ||
| Body composition and overweight of liver transplant recipients | Q84833984 | ||
| Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation | Q85361314 | ||
| Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes | Q86615758 | ||
| Resting energy expenditure, body composition, and dietary intake: a longitudinal study before and after liver transplantation | Q87092168 | ||
| Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation | Q88016820 | ||
| Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis | Q88147162 | ||
| Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis | Q35649534 | ||
| Transplanted liver: consequences of denervation for liver functions | Q35894480 | ||
| Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. | Q35903784 | ||
| New-onset diabetes after liver transplantation: from pathogenesis to management. | Q36138559 | ||
| Long-term medical management of the liver transplant recipient: what the primary care physician needs to know | Q36399571 | ||
| Nonalcoholic fatty liver disease and liver transplantation. | Q36429189 | ||
| Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival | Q36673799 | ||
| Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. | Q36696738 | ||
| Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia | Q36802569 | ||
| New onset diabetes mellitus after solid organ transplantation | Q36993705 | ||
| Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients | Q37064456 | ||
| Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. | Q37192537 | ||
| Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances | Q37439861 | ||
| Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis | Q37548563 | ||
| Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. | Q37562126 | ||
| Mammalian target of rapamycin and diabetes: what does the current evidence tell us? | Q37570804 | ||
| Metabolic syndrome and its components after liver transplantation: incidence, prevalence, risk factors, and implications | Q37603993 | ||
| Posttransplant metabolic syndrome: an epidemic waiting to happen | Q37638639 | ||
| Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation | Q37638642 | ||
| The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle. | Q37727810 | ||
| Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation | Q37730690 | ||
| Metabolic syndrome and liver transplantation: a review and guide to management | Q37745416 | ||
| Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. | Q38008136 | ||
| The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis | Q38180333 | ||
| Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities | Q38212215 | ||
| CKD and nonalcoholic fatty liver disease | Q38236189 | ||
| Clinical mycophenolic acid monitoring in liver transplant recipients | Q38242804 | ||
| The role of everolimus in liver transplantation | Q38248591 | ||
| Orthotopic liver transplantation in non-alcoholic fatty liver disease patients. | Q38290718 | ||
| Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk | Q38424050 | ||
| The treatment of diabetes mellitus of patients with chronic liver disease | Q38599108 | ||
| Post-transplantation diabetes-state of the art. | Q38657521 | ||
| Risk factors of metabolic syndrome after liver transplantation. | Q38668209 | ||
| Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation | Q38682089 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| liver transplantation | Q1368191 | ||
| postoperative complications | Q18478450 | ||
| orthotopic liver transplantation | Q106649759 | ||
| P304 | page(s) | 8869-8882 | |
| P577 | publication date | 2016-10-28 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study | |
| P478 | volume | 22 |
| Q40232067 | Cirrhosis is a risk factor for atrial fibrillation: A nationwide, population-based study |
| Q57810495 | Epidemiology and Prognostic Importance of Atrial Fibrillation in Kidney Transplant Recipients: A Meta-Analysis |
| Q58603834 | Liver transplantation and atrial fibrillation: A meta-analysis |
| Q91160910 | Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality |
| Q64254113 | The Changing Face of Liver Transplantation in the United States: The Effect of HCV Antiviral Eras on Transplantation Trends and Outcomes |
Search more.